Steroid class action certified on appeal
This article was originally published in The Tan Sheet
A California appellate court in Los Angeles sides with a class action certification attempt on appeal against GNC about steroid-containing supplements. The court's Jan. 21 1decision reverses a lower court's rejection of plaintiff Diego Martinez's class certification attempt. The previous rejection was based on an erroneous legal assumption - "that common issues did not predominate because class members would be required to individually litigate issues of causation and injury." Martinez attempted to certify a class of anyone who purchased products from GNC containing androstenediol in California between 2000 and 2004. He alleged damages based on GNC's deceptive conduct. GNC said it ceased selling so-called supplements with androstenediol, a schedule III controlled substance, in March 2004 (2"The Tan Sheet" Oct. 27, 2003)
You may also be interested in...
Androstenedione would be regulated as a controlled substance under legislation offered by Sen. Joseph Biden (D-Del.), and co-sponsored by Sens. Orrin Hatch (R-Utah), Tom Harkin (D-Iowa) and Charles Grassley (R-Iowa)
Alignment with other relevant regulations, including medtech, should be a main priority for the European Medicines Agency when developing guidance on the use of artificial intelligence, according to MedTech Europe’s director for international affairs.
US Health and Human Service Department questions recent federal court decision striking down the government’s policy of allowing plans to broadly exclude manufacturer copay assistance from counting toward patient deductibles or out-of-pocket maximums.